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The birth of the evidence-based medicine (EBM) movement in the
early 1990s generated a greater interest in measuring the extent to
which scientific knowledge was appropriately applied to therapeu-
tic decisions. Investigators sought to challenge the widespread
belief that only a minority of treatments provided to patients were
based upon the best available scientific evidence. In 1995 Ellis and
colleagues, many of whom were among the greatest champions
of the evidence-based movement, published one of the earliest
attempts to quantify the diffusion of evidence-based treatment into
everyday practice [1]. In their study, investigators identified the
primary diagnosis, and the therapy used to treat each diagnosis, for
109 patients admitted over a 1-month period to the inpatient ward
at a UK hospital. Through an extensive literature search, the inves-
tigators determined that the medical literature supported 82% of
the diagnosis–therapy pairs and 52% were supported by data from
randomized controlled trials. Similar studies quantifying adher-
ence to ‘best evidence’ built upon the quality assurance work
of Donabedian [2] and helped lay the foundation of modern day
research that examines the process of moving empiric data from
research to clinical practice – knowledge translation [3,4] – and
forms the basis of popular quality improvement initiatives around
the world.
Modern day knowledge translation research and quality
improvement initiatives serve as excellent examples of the current
importance given to measuring adherence to the best scientific
evidence. In 1999 the US Congress formed the Agency of Health
Research and Quality (AHRQ) and tasked it, among other things,
to ‘promote health care quality improvement by conducting and
supporting the synthesis and dissemination of available scientific
evidence for use by patients, consumers, practitioners, providers,
purchasers, policy makers, and educators’ [5]. In 2010 it is esti-
mated that over $370 million US dollars will be appropriated to
the AHRQ towards achieving this goal [6]. While considerable,
this amount represents only 1% of the total budget of the National
Institutes of Health [7]. Despite greater interest in EBM and
greater funding to study EBM penetration, numerous studies
involving tens of thousands of patients illustrate that a significant
proportion of eligible patients in the USA and the UK do not
receive therapies known to improve outcomes [8–12]. This fact is
widely accepted and arguably justifies a need for even greater
research spending aimed at using EBM to improve patient out-
comes [13].
It is within this context that we consider the current study
conducted by Ayre and Walters [14]. In their analysis, the authors
seek to repeat a study similar in design to that conducted by Ellis
hypothesizing that the rapid expansion of published evidence since
1995 comes with a concomitant expansion in the appropriate use
of EBM at the bedside. A total of 150 diagnosis–therapy pairs from
102 patients were identified over a 1-month period from an inpa-
tient service in the UK. A literature search identified if the therapy
for each pair was supported by evidence. The authors determined
that only 52% of diagnosis–therapy pairs were supported by sys-
tematic reviews or randomized controlled trials, the two highest
levels of evidence considered. An additional 32% of pairs were
based upon non-experimental evidence. When these numbers are
compared with Ellis, and other similar studies, there has been
no real change in the proportion of medical inpatients receiving
evidence-based therapies.
The study has a number of limitations that are worth mention-
ing. First, each patient’s diagnosis was retrospectively abstracted
from the medical record by a single individual. No definitions
or confirmations of the diagnoses are provided, preventing the
reader from assessing the validity of a diagnostic label. Second, no
attempt was made to exclude patients with a given diagnosis who
were ineligible for the highest level of evidence because of con-
traindications. For example, anticoagulation is contraindicated in
patients with a deep venous thrombosis who have an active gas-
trointestinal hemorrhage. These first two limitations could dra-
matically impact the proportion of diagnosis–therapy pairs that are
evidence-based. Third, no data is provided that would help the
reader assess the generalizability of this study, including patient
demographics, and make-up of the inpatient medical team. It is
unlikely that results from 150 patients from a single centre gener-
alize to other patients/centres. Moreover, no information is pro-
vided about the whether institution in which patients were treated
engages in activities known to improve EBM adherence such as
educational outreach, pay for performance, behavioral audit and
feedback, and computerized reminders [12,15]. Fourth, the authors
provide no estimate of precision (95% confidence intervals) for
their proportions. Given the small numbers in the study the esti-
mates are likely to have only moderate precision. In general, the
study would be greatly strengthened had the authors taken a more
evidence-based approach to the design of the study and reporting
of the results [16,17].
So what can we learn from this limited study that re-illustrates
the well known fact: clinicians mostly adhere to evidence-based
therapies but not all of the time? First, the absence of 100%
adherence to EBM at the bedside persists despite the rapid increase
in published evidence, greater international focus on quality
and safety, and a better understanding of how to bridge the gap
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between what we know and how we practice. This observation,
while not unexpected, reinforces prior and ongoing work by
others. Second, this study illustrates the need to move beyond just
describing rates of EBM use and focus on characterizing the
causes of non-adherence. Understanding why evidence is not
adopted characterizes much of the research conducted by knowl-
edge translation investigators and investigators already know a
great deal about the barriers to adoption of evidence [4,18]. Efforts
to improve adherence to evidence have been successful in numer-
ous contexts [9,12], and more attention to this goal is certainly
warranted.
Finally, novel hypotheses explaining the persistence in non-
perfect EBM adherence must be considered. It may very well be
that a goal of 100% adherence to evidence-based therapies does
not represent best clinical practice. Exceptions exist to every rule,
and the duty of the physician is to individual patients. While
traditional efforts to improve the care of patients focus on altering
provider and system-level behavior to conform to the EBM para-
digm [4], an alternative approach would be to consider re-shaping
the EBM paradigm to incorporate routine and appropriate aspects
of care not rooted in empiric observation. Some have proposed
this approach as casuistic alternative to EBM [19]. One of the
reasons adherence to EBM may not be 100% is because phy-
sicians may continue to rely upon non-evidentiary warrants for
therapeutic decisions. In other words, one could hypothesize that
EBM has failed to change physician’s use of experiential evi-
dence, pathophysiologic rationale, patient goals and values, and
other system factors when making therapeutic decisions [19]. This
hypothesis is supported by the multiple diagnosis–therapy pairs
listed as category 3 (convincing non-experimental evidence) or 4
(no contrary evidence) where providers likely relied upon expe-
rience and patient preference. For example, use of non-steroidal
anti-inflammatory drugs for musculoskeletal chest pain may
not have been demonstrated in a randomized controlled trial to
provide benefit over placebo, but when a patient has an excellent
individual response to the therapy, it is hard to argue to withhold
it. Similarly, while nebulized delivery of inhaled medication does
not appear to have advantages compared with using a spacer with
a metered dose inhaler, withholding a nebulizer from a patient in
respiratory distress who feels that she gets more rapid relief from
that delivery system does not seem to practicing patient-centred
medicine.
In sum, Ayer and Walters report [14], while suffering from
many of the same limitations as studies by Ellis and others,
suggests that the nature of the practice of medicine has changed
very little over the last decade, a decade dominated by the EBM
movement. The author’s appear a bit chagrined by this fact, and
certainly more can be done to ensure that clinicians take the
knowledge gained from clinical research into account when
caring for patients. But perhaps they should not consider the
results a failing of EBM. Instead, it may be that optimal practice
of medicine should rely on empirical evidence only much of the
time, and appropriately base some decisions on more compelling
and non-evidentiary reasons.
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